NASDAQ:SERA Sera Prognostics Q2 2026 Earnings Report $1.94 +0.03 (+1.30%) As of 10:12 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Sera Prognostics EPS ResultsActual EPSN/AConsensus EPS -$0.14Beat/MissN/AOne Year Ago EPSN/ASera Prognostics Revenue ResultsActual RevenueN/AExpected Revenue$0.07 millionBeat/MissN/AYoY Revenue GrowthN/ASera Prognostics Announcement DetailsQuarterQ2 2026Date8/5/2026TimeAfter Market ClosesConference Call DateWednesday, August 5, 2026Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Sera Prognostics Earnings HeadlinesPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CAREJuly 9, 2026 | prnewswire.comSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORSJune 30, 2026 | prnewswire.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.July 14 at 1:00 AM | Porter & Company (Ad)SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTHJune 24, 2026 | prnewswire.comSERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCYJune 23, 2026 | prnewswire.comSera Prognostics Holds 2026 Annual Stockholders MeetingJune 4, 2026 | tipranks.comSee More Sera Prognostics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email. Email Address About Sera PrognosticsSera Prognostics (NASDAQ:SERA) is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery. Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test. The company has secured relevant regulatory clearances and reimbursement pathways, and continues to explore additional clinical applications for its proteomic platform. Collaborative efforts with academic institutions and health systems support ongoing studies aimed at demonstrating the test’s utility in diverse patient populations. Headquartered in Salt Lake City, Utah, Sera Prognostics is led by President and Chief Executive Officer Zachary Carr, who brings experience in commercializing diagnostic technologies. Under his leadership, the company has built a multidisciplinary team of professionals in molecular diagnostics, clinical operations, regulatory affairs, and market access. Sera Prognostics remains dedicated to advancing maternal–fetal health and expanding its footprint through partnerships with healthcare organizations and research sponsors.View Sera Prognostics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Analysts See Major Upside for These 5 StocksMarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth Upcoming Earnings Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026)Bank of New York Mellon (7/15/2026)Morgan Stanley (7/15/2026)Progressive (7/15/2026)The PNC Financial Services Group (7/15/2026)Elevance Health (7/15/2026)Johnson & Johnson (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
